How does a medicine get onto the Specialities List?

The sequence: authorisation first, reimbursement second

Without Swissmedic authorisation under the Therapeutic Products Act there is no admission. Only afterwards does the FOPH assess efficacy, appropriateness and cost effectiveness under Art. 65 of the Health Insurance Ordinance. In practice the price dossier is prepared in parallel with the authorisation procedure and filed right after the decision.

The filing window matters: if the holder files within 60 days of authorisation, the claim to accelerated handling under Art. 31b of the Health Care Benefits Ordinance is preserved. Filing later forfeits that advantage and means waiting for the next ordinary cycle.

What the admission dossier must contain

This is not an authorisation dossier. It consists of a foreign price comparison against the reference countries, a therapeutic cross comparison using daily treatment costs, a multi-year turnover estimate, the approved professional information, the requested price and, where claimed, the justification for an innovation premium.

• Foreign price comparison: ex-factory equivalents in the reference countries, with sources and a cut-off date.
• Therapeutic cross comparison: comparator products from the same IT group, dosing, cost per day.
• Turnover estimate: expected patient numbers and sales, usually across three to five years.
• Professional information: the version approved by Swissmedic, with the exact indication wording.
• Innovation premium: added clinical benefit over the existing standard, supported by trial data.

The role of the Federal Drug Commission

The Federal Drug Commission, known as EAK in German and CFM in French and Italian, advises the FOPH on admissions, limitations and contested price questions. It is an extra-parliamentary expert body with physicians, pharmacists, insurers, cantons, patient organisations and industry. It recommends rather than decides.

The commission meets several times a year on fixed dates. Missing a meeting because documents are incomplete or the FOPH has follow-up questions typically costs several months. The meeting calendar is therefore the single most important planning factor in the whole procedure.

From filing to publication: the steps

On receipt the FOPH checks completeness, recalculates both comparisons itself, obtains a commission recommendation where needed, negotiates the price, grants the right to be heard on the intended outcome and finally issues its ruling. Only the monthly publication makes the entry effective.

1. File the request with a complete dossier within 60 days of authorisation.
2. Formal completeness check by the FOPH, with any requests for further documents.
3. The FOPH recalculates the foreign price comparison and the therapeutic cross comparison.
4. Tabling and assessment by the Federal Drug Commission, with a recommendation on price and limitation.
5. Price negotiation, in some cases with a price model or rebate model.
6. Right to be heard on the draft ruling, with the holder's written response.
7. FOPH ruling and publication in the Specialities List effective the first of the month.

Deadlines, time-limited admission and price models

Art. 31b of the Health Care Benefits Ordinance gives the FOPH 60 days from a complete request. That clock pauses while documents are missing or a commission assessment is pending, which is why real duration is far longer. Admission is often time-limited or tied to a limitation so reimbursement can start at all.

Realistically, four to nine months often pass between authorisation and publication. For very expensive therapies with a price model and several commission rounds, twelve to eighteen months is not unusual.

Rejection, appeal and the usual causes of delay

If the FOPH rejects the request or sets a lower price than requested, the holder may appeal to the Federal Administrative Court within 30 days and then to the Federal Supreme Court. The alternative is a fresh request with an adjusted price or a narrower limitation.

• An incomplete or outdated foreign price comparison with undocumented sources.
• Disagreement over the correct comparator in the therapeutic cross comparison.
• An over-optimistic turnover estimate that has to be corrected mid-procedure.
• A missed commission meeting, and with it the wait until the next one.
• Protracted price model negotiations for very expensive one-off therapies.